Strategies for prevention of neonatal chronic lung disease.
Chronic lung disease (CLD) of prematurity remains a substantial problem despite modern perinatal and neonatal care. CLD remains related to gestational age and lung immaturity, although it has become clear that severe initial lung disease is not a prerequisite for CLD to develop. Attempts to prevent CLD to date have not adequately addressed the multifactorial nature of the complex pathophysiology that leads to CLD. Thus, results have been modest at best. Prevention of CLD will require a multifaceted approach with specific interventions and care practices focused on different aspects of the pathway that leads to CLD. This review considers new information related to causation of CLD and the magnitude of the effect of prevention strategies tested to date. This article also advances the hypothesis that CLD is preventable with a global strategy of minimizing inciting events, optimizing management, and specific therapies aimed at intrinsic vulnerabilities.
Cole
C H
CH
Division of Newborn Medicine, The Floating Hospital for Children, Tufts University School of Medicine, Boston, MA, USA. ccole@lifespan.org
Fiascone
J M
JM
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008171:Lung Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D012121:Respiration, Artificial / Q000009:adverse effects / Q000379:methods; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014815:Vitamins; D013973:Thyrotropin-Releasing Hormone